GLR Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

GLR Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,538	Closed	-$1.58M	–	118
2026 Q1	$1.58M	Buy	+3,538	New	+$1.65M	0.86%	33

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GLR Partners's VRTX Position: Q2 2026 in Review

GLR Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 3,538 shares — an estimated $1.58M sold.

GLR Partners first reported a position in VRTX in Q1 2026 and held it in 1 quarter. The position peaked at $1.58M in Q1 2026. 1,743 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

GLR Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
GLR Partners sold 3,538 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.58M.
GLR Partners first reported a position in Vertex Pharmaceuticals in Q1 2026 and held it in 1 quarter.
GLR Partners's Vertex Pharmaceuticals position peaked at $1.58M in Q1 2026.
1,743 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on GLR Partners's 13F filing for Q2 2026, filed 27 Jul 2026.